Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Bullous Pemphigoid
NCT03099538Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Aug 2017
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ixekizumab in Bullous Pemphigoid (BP), sponsored by Mayo Clinic. Started Aug 2017; status: completed.
02
Drugs
ixekizumab
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT03099538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099538.